{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T04:02:33Z","timestamp":1790827353630,"version":"4.1.0"},"reference-count":225,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,5,27]],"date-time":"2026-05-27T00:00:00Z","timestamp":1779840000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,7,24]],"date-time":"2026-07-24T00:00:00Z","timestamp":1784851200000},"content-version":"vor","delay-in-days":58,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cancer Cell Int"],"DOI":"10.1186\/s12935-026-04349-5","type":"journal-article","created":{"date-parts":[[2026,5,27]],"date-time":"2026-05-27T12:46:07Z","timestamp":1779885967000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Molecular convergence in gallbladder cancer: MEK\u2013ERK signalling at the crossroads of oncogenic hubs and pathway cross-talks"],"prefix":"10.1186","volume":"26","author":[{"ORCID":"https:\/\/orcid.org\/0009-0003-0109-4993","authenticated-orcid":false,"given":"Deeptima","family":"Jaiswar","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6997-1054","authenticated-orcid":false,"given":"Manjusha","family":"Dixit","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,5,27]]},"reference":[{"key":"4349_CR1","unstructured":"International Agency for. Research on Cancer, T. Global Cancer Observatory. Accessed: https:\/\/gco.iarc.who.int\/en 24th April 2025."},{"key":"4349_CR2","doi-asserted-by":"publisher","first-page":"93","DOI":"10.5114\/ceh.2019.85166","volume":"5","author":"P Rawla","year":"2019","unstructured":"Rawla P, Sunkara T, Thandra KC, Barsouk A. Epidemiology of gallbladder cancer. Clin Exp Hepatol. 2019;5:93.","journal-title":"Clin Exp Hepatol"},{"key":"4349_CR3","doi-asserted-by":"publisher","first-page":"32","DOI":"10.3390\/pathophysiology29010005","volume":"29","author":"EV Silina","year":"2022","unstructured":"Silina EV, et al. Oxidative Stress and Free Radical Processes in Tumor and Non-Tumor Obstructive Jaundice: Influence of Disease Duration, Severity and Surgical Treatment on Outcomes. Pathophysiology. 2022;29:32\u201351.","journal-title":"Pathophysiology"},{"key":"4349_CR4","doi-asserted-by":"crossref","unstructured":"Riddell ZC, Corallo C, Albazaz R, Foley KG. Gallbladder polyps and adenomyomatosis. Br J Radiol. 2023;96(1142):20220115.","DOI":"10.1259\/bjr.20220115"},{"key":"4349_CR5","doi-asserted-by":"publisher","first-page":"1051","DOI":"10.1080\/01635581.2023.2180824","volume":"75","author":"J Chen","year":"2023","unstructured":"Chen J, et al. Body Mass Index and Cancer Risk: An Umbrella Review of Meta-Analyses of Observational Studies. Nutr Cancer. 2023;75:1051\u20131064.","journal-title":"Nutr Cancer"},{"key":"4349_CR6","doi-asserted-by":"publisher","first-page":"699","DOI":"10.4103\/ijmr.IJMR_201_19","volume":"154","author":"K Mishra","year":"2021","unstructured":"Mishra K, et al. Risk factors for gallbladder cancer development in northern India: A gallstones-matched, case-control study. Indian J Med Res. 2021;154:699\u2013706.","journal-title":"Indian J Med Res"},{"key":"4349_CR7","doi-asserted-by":"publisher","first-page":"2967","DOI":"10.3748\/wjg.v26.i22.2967","volume":"26","author":"MH Yu","year":"2020","unstructured":"Yu MH, Kim YJ, Park HS, Jung S. I. Benign gallbladder diseases: Imaging techniques and tips for differentiating with malignant gallbladder diseases. World J Gastroenterol. 2020;26:2967\u20132986.","journal-title":"World J Gastroenterol"},{"key":"4349_CR8","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1016\/j.suronc.2019.09.006","volume":"31","author":"EE Montalvo-Jave","year":"2019","unstructured":"Montalvo-Jave EE, et al. Molecular pathways and potential biomarkers in gallbladder cancer: A comprehensive review. Surg Oncol. 2019;31:83\u201389.","journal-title":"Surg Oncol"},{"key":"4349_CR9","doi-asserted-by":"publisher","first-page":"619","DOI":"10.1016\/j.soc.2019.06.005","volume":"28","author":"L Cherkassky","year":"2019","unstructured":"Cherkassky L, D\u2019Angelica M. Gallbladder Cancer: Managing the Incidental Diagnosis. Surg Oncol Clin N Am. 2019;28:619\u2013630.","journal-title":"Surg Oncol Clin N Am"},{"key":"4349_CR10","doi-asserted-by":"publisher","unstructured":"Siddiqui A, et al. The Genetic and Epidemiological Dimensions of Gallbladder Cancer: Toward Effective Therapeutic Strategies. Curr Gene Ther. June 2025;25; https:\/\/doi.org\/10.2174\/0115665232366089250610083533","DOI":"10.2174\/0115665232366089250610083533"},{"key":"4349_CR11","doi-asserted-by":"crossref","unstructured":"Yoon H, Yoo C. Systemic Therapy for Advanced Biliary Tract Cancers in 2026: Current Standard of Care and Emerging Therapeutic Strategies. J Gastroenterol Hepatol. Feb. 2026;41(2):516\u2013531.","DOI":"10.1111\/jgh.70208"},{"issue":"10","key":"4349_CR12","doi-asserted-by":"publisher","first-page":"1317","DOI":"10.4251\/wjgo.v13.i10.1317","volume":"13","author":"K Okumura","year":"2021","unstructured":"Okumura K, et al. Gallbladder cancer: Historical treatment and new management options. World J Gastrointest Oncol. 2021;13(10):1317\u20131335.","journal-title":"World J Gastrointest Oncol"},{"key":"4349_CR13","doi-asserted-by":"publisher","first-page":"5257","DOI":"10.3390\/cancers13215257","volume":"13","author":"H Kuipers","year":"2021","unstructured":"Kuipers H, et al. Gallbladder Cancer: Current Insights in Genetic Alterations and Their Possible Therapeutic Implications. Cancers (Basel). 2021;13:5257.","journal-title":"Cancers (Basel)"},{"key":"4349_CR14","doi-asserted-by":"crossref","unstructured":"D\u2019Afonseca V, Arencibia AD, Echeverr\u00eda-Vega A et al. Identification of Altered Genes in Gallbladder Cancer as Potential Driver Mutations for Diagnostic and Prognostic Purposes: A Computational Approach. Cancer Inform. 2020;19:1176935120922154.","DOI":"10.1177\/1176935120922154"},{"key":"4349_CR15","first-page":"763","volume":"12","author":"HJ Chang","year":"1999","unstructured":"Chang HJ, Kim SW, Kim YT, Kim WH. Loss of heterozygosity in dysplasia and carcinoma of the gallbladder. Mod Pathol. 1999;12:763\u2013769.","journal-title":"Mod Pathol"},{"key":"4349_CR16","doi-asserted-by":"publisher","first-page":"393","DOI":"10.1007\/s00428-015-1720-0","volume":"466","author":"AP Moy","year":"2015","unstructured":"Moy AP, Shahid M, Ferrone CR, et al. Microsatellite instability in gallbladder carcinoma. Virchows Arch. 2015;466:393\u2013402.","journal-title":"Virchows Arch"},{"key":"4349_CR17","doi-asserted-by":"publisher","first-page":"12298","DOI":"10.1038\/s41598-021-91804-0","volume":"11","author":"E Ueta","year":"2021","unstructured":"Ueta E, et al. Extracellular vesicle-shuttled miRNAs as a diagnostic and prognostic biomarker and their potential roles in gallbladder cancer patients. Sci Rep. 2021;11:12298.","journal-title":"Sci Rep"},{"key":"4349_CR18","doi-asserted-by":"publisher","first-page":"104816","DOI":"10.1016\/j.isci.2022.104816","volume":"25","author":"P Yang","year":"2022","unstructured":"Yang P, et al. Exosomal MicroRNA signature acts as an efficient biomarker for non-invasive diagnosis of gallbladder carcinoma. iScience. 2022;25:104816.","journal-title":"iScience"},{"key":"4349_CR19","doi-asserted-by":"publisher","first-page":"5573","DOI":"10.3390\/ijms20225573","volume":"20","author":"X Zhang","year":"2019","unstructured":"Zhang X, et al. Mechanisms and Functions of Long Non-Coding RNAs at Multiple Regulatory Levels. Int J Mol Sci. 2019;20:5573.","journal-title":"Int J Mol Sci"},{"key":"4349_CR20","doi-asserted-by":"crossref","unstructured":"Mishra S, Kumari S, Srivastava P, Pandey A. S.Shukla, N.Husain.Genomic profiling of gallbladder carcinoma: Targetable mutations and pathways involved. Pathol - Res Pract. 2022,232:153806 .","DOI":"10.1016\/j.prp.2022.153806"},{"key":"4349_CR21","doi-asserted-by":"crossref","unstructured":"de Bitter, T.J.J., de Reuver, P.R., de Savornin Lohman, E.A.J. et al. Comprehensive clinicopathological and genomic profiling of gallbladder cancer reveals actionable targets in half of patients. npj Precis. Onc. 2022;6:83.","DOI":"10.1038\/s41698-022-00327-y"},{"key":"4349_CR22","doi-asserted-by":"publisher","first-page":"153806","DOI":"10.1016\/j.prp.2022.153806","volume":"232","author":"S Mishra","year":"2022","unstructured":"Mishra S, et al. Genomic profiling of gallbladder carcinoma: Targetable mutations and pathways involved. Pathol Res Pract. 2022;232:153806.","journal-title":"Pathol Res Pract"},{"key":"4349_CR23","doi-asserted-by":"publisher","first-page":"540","DOI":"10.1016\/j.trecan.2020.03.003","volume":"6","author":"PK Tiwari","year":"2020","unstructured":"Tiwari PK. Epigenetic Biomarkers in Gallbladder Cancer. Trends Cancer. 2020;6:540\u2013543.","journal-title":"Trends Cancer"},{"key":"4349_CR24","doi-asserted-by":"publisher","first-page":"356","DOI":"10.1007\/s13193-013-0240-0","volume":"4","author":"M Tewari","year":"2013","unstructured":"Tewari M, Agarwal A, Mishra RR, Meena RN, Shukla HS. Epigenetic changes in carcinogenesis of gallbladder. Indian J Surg Oncol. 2013;4:356\u2013361.","journal-title":"Indian J Surg Oncol"},{"key":"4349_CR25","doi-asserted-by":"publisher","unstructured":"Sharma N, Tomar A, Tiwari PQK. Gallbladder Cancer: Epigenetic Landscape, Targeted Therapy, and Prospect of Epitherapy. In: Kumar Shukla V, Pandey M, Dixit R, editors. Gallbladder Cancer. Singapore: Springer; 2023; https:\/\/doi.org\/10.1007\/978-981-19-6442-8_12","DOI":"10.1007\/978-981-19-6442-8_12"},{"key":"4349_CR26","doi-asserted-by":"publisher","first-page":"76","DOI":"10.1186\/s13045-019-0760-3","volume":"12","author":"Y Lin","year":"2019","unstructured":"Lin Y, Xu J, Lan H. Tumor-associated macrophages in tumor metastasis: biological roles and clinical therapeutic applications. J Hematol Oncol. 2019;12:76.","journal-title":"J Hematol Oncol"},{"key":"4349_CR27","doi-asserted-by":"publisher","first-page":"1","DOI":"10.14216\/kjco.24001","volume":"20","author":"S Ahuja","year":"2024","unstructured":"Ahuja S, Khan AA, Verma P, Zaheer S. Association of tumor budding and tumor infiltrating lymphocytes with clinicopathological parameters in gallbladder carcinoma. Korean J Clin Oncol. 2024;20:1\u20135.","journal-title":"Korean J Clin Oncol"},{"key":"4349_CR28","doi-asserted-by":"publisher","first-page":"35","DOI":"10.2217\/imt-2022-0191","volume":"15","author":"J Kassab","year":"2023","unstructured":"Kassab J, et al. Update on immunotherapy in the management of gallbladder cancer. Immunotherapy. 2023;15:35\u201342.","journal-title":"Immunotherapy"},{"key":"4349_CR29","doi-asserted-by":"crossref","unstructured":"Shioi Y, Osakabe M, Yanagawa N, Nitta H, Sasaki A, Sugai T. Analysis of Somatic Copy Number Alterations in Biliary Tract Carcinoma Using a Single Nucleotide Polymorphism Array. Future Sci OA. 2021;8(1):FSO766.","DOI":"10.2144\/fsoa-2021-0057"},{"key":"4349_CR30","doi-asserted-by":"publisher","first-page":"333","DOI":"10.1007\/s00432-009-0751-9","volume":"136","author":"MI Hassan","year":"2010","unstructured":"Hassan MI, Naiyer A, Ahmad F. Fragile histidine triad protein: structure, function, and its association with tumorogenesis. J Cancer Res Clin Oncol. 2010;136:333\u2013350.","journal-title":"J Cancer Res Clin Oncol"},{"key":"4349_CR31","doi-asserted-by":"publisher","first-page":"3978","DOI":"10.3748\/wjg.v23.i22.3978","volume":"23","author":"A Sharma","year":"2017","unstructured":"Sharma A, Sharma KL, Gupta A, Yadav A, Kumar A. Gallbladder cancer epidemiology, pathogenesis and molecular genetics: Recent update. World J Gastroenterol. 2017;23:3978\u20133998.","journal-title":"World J Gastroenterol"},{"key":"4349_CR32","unstructured":"U.S. Department of Health and Human Services. (n.d.). David functional annotation bioinformatics Microarray analysis. National Institutes of Health. https:\/\/davidbioinformatics.nih.gov\/ Accessed: 24th April 2025."},{"key":"4349_CR33","unstructured":"Kegg pathway database. https:\/\/www.genome.jp\/kegg\/pathway.html Accessed: 24th April 2025."},{"key":"4349_CR34","doi-asserted-by":"publisher","unstructured":"Sherman BT, Hao M, Qiu J, Jiao X, Baseler MW, Lane HC, Imamichi T, Chang W. DAVID: a web server for functional enrichment analysis and functional annotation of gene lists (2021 update). Nucleic Acids Res. March 2022;23: https:\/\/doi.org\/10.1093\/nar\/gkac194","DOI":"10.1093\/nar\/gkac194"},{"issue":"1","key":"4349_CR35","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1038\/nprot.2008.211","volume":"4","author":"DW Huang","year":"2009","unstructured":"Huang DW, Sherman BT, Lempicki RA. Systematic and integrative analysis of large gene lists using DAVID Bioinformatics Resources. Nat Protoc 2009;4(1):44\u201357.","journal-title":"Nat Protoc"},{"issue":"5","key":"4349_CR36","doi-asserted-by":"publisher","first-page":"434","DOI":"10.1053\/j.semnuclmed.2020.04.002","volume":"50","author":"F Moradi","year":"2020","unstructured":"Moradi F, Iagaru A. The Role of Positron Emission Tomography in Pancreatic Cancer and Gallbladder Cancer. Semin Nucl Med. 2020;50(5):434\u2013446.","journal-title":"Semin Nucl Med"},{"key":"4349_CR37","doi-asserted-by":"publisher","first-page":"e416","DOI":"10.18295\/squmj.2016.16.04.003","volume":"16","author":"NO Machado","year":"2016","unstructured":"Machado NO. Porcelain Gallbladder: Decoding the malignant truth. Sultan Qaboos Univ Med J. 2016;16:e416\u2013e421.","journal-title":"Sultan Qaboos Univ Med J"},{"key":"4349_CR38","doi-asserted-by":"publisher","first-page":"311","DOI":"10.1007\/s10353-021-00710-2","volume":"53","author":"N Calomino","year":"2021","unstructured":"Calomino N, et al. Porcelain gallbladder and its relationship to cancer. Eur Surg. 2021;53:311\u2013316.","journal-title":"Eur Surg"},{"key":"4349_CR39","doi-asserted-by":"crossref","unstructured":"Jose E, Dawes L. Gallbladder and Biliary Diseases: More Common in Women, More Severe in Men.Principles of Gender-Specific Medicine,2004;1:446-453.","DOI":"10.1016\/B978-012440905-7\/50310-8"},{"key":"4349_CR40","first-page":"77","volume":"75","author":"AB Lowenfels","year":"1985","unstructured":"Lowenfels AB, Lindstr\u00f6m CG, Conway MJ, Hastings PR. Gallstones and risk of gallbladder cancer. J Natl Cancer Inst. 1985;75:77\u201380.","journal-title":"J Natl Cancer Inst"},{"key":"4349_CR41","doi-asserted-by":"publisher","first-page":"e1006756","DOI":"10.1371\/journal.pgen.1006756","volume":"13","author":"J Lorenzo Bermejo","year":"2017","unstructured":"Lorenzo Bermejo J, et al. Subtypes of Native American ancestry and leading causes of death: Mapuche ancestry-specific associations with gallbladder cancer risk in Chile. PLoS Genet. 2017;13:e1006756.","journal-title":"PLoS Genet"},{"issue":"3","key":"4349_CR42","doi-asserted-by":"publisher","first-page":"361","DOI":"10.1016\/j.amjsurg.2011.12.002","volume":"203","author":"I Nir","year":"2011","unstructured":"Nir I, Wiggins CL, Morris K, Rajput A. Diversification. and trends in biliary tree cancer among the three major ethnic groups in the state of New Mexico. Am J Surj. 2011;203(3):361\u2013365.","journal-title":"Am J Surj"},{"key":"4349_CR43","doi-asserted-by":"publisher","first-page":"32","DOI":"10.21037\/cco.2019.07.12","volume":"8","author":"M Salazar","year":"2019","unstructured":"Salazar M, Ituarte C, Abriata MG, Santoro F, Arroyo G. Gallbladder cancer in South America: epidemiology and prevention. Chin Clin Oncol. 2019;8:32.","journal-title":"Chin Clin Oncol"},{"key":"4349_CR44","doi-asserted-by":"publisher","first-page":"35","DOI":"10.21037\/cco.2019.07.03","volume":"8","author":"MR Acharya","year":"2019","unstructured":"Acharya MR, Patkar S, Parray A, Goel M. Management of gallbladder cancer in India. Chin Clin Oncol. 2019;8:35.","journal-title":"Chin Clin Oncol"},{"key":"4349_CR45","doi-asserted-by":"publisher","first-page":"4114","DOI":"10.3390\/ijms21114114","volume":"21","author":"B Bojkov\u00e1","year":"2020","unstructured":"Bojkov\u00e1 B, Winklewski PJ, Wszedybyl-Winklewska M. Dietary Fat and Cancer-Which Is Good, Which Is Bad, and the Body of Evidence. Int J Mol Sci. 2020;21:4114.","journal-title":"Int J Mol Sci"},{"key":"4349_CR46","doi-asserted-by":"publisher","first-page":"e89368","DOI":"10.1371\/journal.pone.0089368","volume":"9","author":"W Borena","year":"2014","unstructured":"Borena W, et al. A prospective study on metabolic risk factors and gallbladder cancer in the metabolic syndrome and cancer (Me-Can) collaborative study. PLoS ONE. 2014;9:e89368.","journal-title":"PLoS ONE"},{"key":"4349_CR47","doi-asserted-by":"publisher","first-page":"70","DOI":"10.1007\/s12672-022-00536-8","volume":"13","author":"H Sun","year":"2022","unstructured":"Sun H, Qi X. The role of insulin and incretin-based drugs in biliary tract cancer: epidemiological and experimental evidence. Discov Onc. 2022;13:70.","journal-title":"Discov Onc"},{"key":"4349_CR48","doi-asserted-by":"publisher","first-page":"943","DOI":"10.1007\/BF01296719","volume":"32","author":"K Wada","year":"1987","unstructured":"Wada K, Tanaka M, Yamaguchi K, Wada K. Carcinoma and polyps of the gallbladder associated with Peutz-Jeghers syndrome. Dig Dis Sci. 1987;32:943\u2013946.","journal-title":"Dig Dis Sci"},{"issue":"43","key":"4349_CR49","doi-asserted-by":"publisher","first-page":"5397","DOI":"10.3748\/wjg.15.5397","volume":"15","author":"M Kopacova","year":"2009","unstructured":"Kopacova M, Tacheci I, Rejchrt S, Bures J. Peutz-Jeghers syndrome: diagnostic and therapeutic approach. World J Gastroenterol. 2009;15(43):5397\u20135408.","journal-title":"World J Gastroenterol"},{"key":"4349_CR50","doi-asserted-by":"publisher","first-page":"592","DOI":"10.1136\/gut.52.4.592","volume":"52","author":"K Hemminki","year":"2003","unstructured":"Hemminki K, Li X. Familial liver and gall bladder cancer: a nationwide epidemiological study from Sweden. Gut. 2003;52(4):592\u2013596.","journal-title":"Gut"},{"key":"4349_CR51","doi-asserted-by":"publisher","unstructured":"Zalevskaja K, Mecklin J-P, Sepp\u00e4l\u00e4 TT. Clinical characteristics of pancreatic and biliary tract cancers in Lynch syndrome: A retrospective analysis from the Finnish National Lynch Syndrome Research Registry. Front Oncol. 2023;13: https:\/\/doi.org\/10.3389\/fonc.2023.1123901","DOI":"10.3389\/fonc.2023.1123901"},{"key":"4349_CR52","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1016\/j.nhccr.2017.06.166","volume":"1","author":"M Balog","year":"2017","unstructured":"Balog M, Kolbe E-W, Lang U, Winde G. Gallbladder polyps in familial adenomatous polyposis. Eur J Mol Clin Med. 2017;1:14.","journal-title":"Eur J Mol Clin Med"},{"key":"4349_CR53","doi-asserted-by":"crossref","unstructured":"Tang J et al. Identification and verification of the key genes involved in gallbladder cancer. Front Immunol.2025,16:1643366.","DOI":"10.3389\/fimmu.2025.1643366"},{"key":"4349_CR54","doi-asserted-by":"crossref","unstructured":"Lin J et al. Genomic characterization of co-existing neoplasia and carcinoma lesions reveals distinct evolutionary paths of gallbladder cancer. Nat Commun. 2021,12:4753.","DOI":"10.1038\/s41467-021-25012-9"},{"key":"4349_CR55","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1038\/s41698-022-00327-y","volume":"6","author":"TJJ de Bitter","year":"2022","unstructured":"de Bitter TJJ, de Reuver PR, de Savornin Lohman EAJ, et al. Comprehensive clinicopathological and genomic profiling of gallbladder cancer reveals actionable targets in half of patients. npj Precis Onc. 2022;6:83.","journal-title":"npj Precis Onc"},{"key":"4349_CR56","doi-asserted-by":"crossref","unstructured":"Walvir NM, Rasool Z, Masoodi S, Hassan AU, Lone RH, Abeer I. p53 Expression in Gallbladder Lesions: A Cross-sectional Study from a Tertiary Care Centre in Northern India.J Clin Diagn Res. 2024;18(1):EC10-EC15.","DOI":"10.7860\/JCDR\/2024\/66785.18967"},{"key":"4349_CR57","doi-asserted-by":"publisher","first-page":"87","DOI":"10.4103\/JCRP.JCRP_7_21","volume":"8","author":"R Kumar","year":"2021","unstructured":"Kumar R, Yadav SK, Singh G, Gupta R, Singh S. Study of Expression of p53 and Ki-67 in Benign, Premalignant, and Malignant Lesions of the Gallbladder. J Cancer Res Pract. 2021;8:87\u201392.","journal-title":"J Cancer Res Pract"},{"key":"4349_CR58","doi-asserted-by":"publisher","first-page":"105306","DOI":"10.1016\/j.esmoop.2025.105306","volume":"10","author":"K Iida","year":"2025","unstructured":"Iida K, et al. Association of KRAS variants with survival and therapeutic outcomes in biliary tract cancers. ESMO Open. 2025;10:105306.","journal-title":"ESMO Open"},{"key":"4349_CR59","doi-asserted-by":"publisher","first-page":"222","DOI":"10.1007\/s00535-025-02303-2","volume":"61","author":"M Zhu","year":"2025","unstructured":"Zhu M, et al. Molecular insights into HER2\/ERBB2 amplification and carcinogenesis in gallbladder cancer associated with pancreaticobiliary maljunction. J Gastroenterol. 2025;61(2):222\u2013238.","journal-title":"J Gastroenterol"},{"key":"4349_CR60","unstructured":"cBioPortal. for Cancer Genomics. https:\/\/www.cbioportal.org. Accessed: 24th April 2025."},{"key":"4349_CR61","doi-asserted-by":"publisher","first-page":"4076","DOI":"10.1200\/JCO.2017.35.15_suppl.4076","volume":"35","author":"M Milind","year":"2017","unstructured":"Milind M, Javle, et al. Precision medicine for gallbladder cancer using somatic copy number amplifications (SCNA) and DNA repair pathway gene alterations. JCO. 2017;35:4076\u20134076.","journal-title":"JCO"},{"key":"4349_CR62","doi-asserted-by":"publisher","first-page":"1086","DOI":"10.1093\/annonc\/mdu006","volume":"25","author":"SG Barreto","year":"2014","unstructured":"Barreto SG, Dutt A, Chaudhary A. A genetic model for gallbladder carcinogenesis and its dissemination. Ann Oncol. 2014;25(6):1086\u20131097.","journal-title":"Ann Oncol"},{"key":"4349_CR63","first-page":"3795","volume":"61","author":"II Wistuba","year":"2001","unstructured":"Wistuba II, et al. Genome-wide allelotyping analysis reveals multiple sites of allelic loss in gallbladder carcinoma. Cancer Res. 2001;61(9):3795\u20133800.","journal-title":"Cancer Res"},{"key":"4349_CR64","doi-asserted-by":"publisher","first-page":"432","DOI":"10.1038\/sj.bjc.6600490","volume":"87","author":"II Wistuba","year":"2002","unstructured":"Wistuba II, et al. High resolution chromosome 3p, 8p, 9q and 22q allelotyping analysis in the pathogenesis of gallbladder carcinoma. Br J Cancer. 2002;87(4):432\u2013440.","journal-title":"Br J Cancer"},{"key":"4349_CR65","first-page":"3581","volume":"61","author":"S Z\u00f6chbauer-M\u00fcller","year":"2001","unstructured":"Z\u00f6chbauer-M\u00fcller S, et al. 5\u2019 CpG island methylation of the FHIT gene is correlated with loss of gene expression in lung and breast cancer. Cancer Res. 2001;61(9):3581\u20133585.","journal-title":"Cancer Res"},{"key":"4349_CR66","doi-asserted-by":"publisher","first-page":"433","DOI":"10.1101\/gad.347542.120","volume":"35","author":"S Pilley","year":"2021","unstructured":"Pilley S, Rodriguez TA, Vousden KH. Mutant p53 in cell-cell interactions. Genes Dev. 2021;35:433\u2013448.","journal-title":"Genes Dev"},{"key":"4349_CR67","doi-asserted-by":"publisher","first-page":"393","DOI":"10.1007\/s00428-015-1720-0","volume":"466","author":"AP Moy","year":"2015","unstructured":"Moy AP, et al. Microsatellite instability in gallbladder carcinoma. Virchows Arch. 2015;466:393\u2013402.","journal-title":"Virchows Arch"},{"key":"4349_CR68","doi-asserted-by":"publisher","first-page":"712","DOI":"10.1002\/jgh3.12576","volume":"5","author":"Y Kai","year":"2021","unstructured":"Kai Y, et al. Success rate of microsatellite instability examination and complete response with pembrolizumab in biliary tract cancer. JGH Open. 2021;5(6):712\u2013716.","journal-title":"JGH Open"},{"key":"4349_CR69","doi-asserted-by":"publisher","first-page":"920","DOI":"10.1016\/j.bbagen.2008.12.004","volume":"1790","author":"HJ Lin","year":"2009","unstructured":"Lin HJ, et al. Seed in soil, with an epigenetic view. Biochim Biophys Acta. 2009;1790(9):920\u2013924.","journal-title":"Biochim Biophys Acta"},{"key":"4349_CR70","doi-asserted-by":"publisher","first-page":"60","DOI":"10.1186\/1476-4598-5-60","volume":"5","author":"M Ducasse","year":"2006","unstructured":"Ducasse M, Brown MA. Epigenetic aberrations and cancer. Mol Cancer. 2006;5:60.","journal-title":"Mol Cancer"},{"key":"4349_CR71","doi-asserted-by":"publisher","first-page":"269","DOI":"10.1007\/s00535-005-1752-3","volume":"41","author":"JC Roa","year":"2006","unstructured":"Roa JC, et al. Promoter methylation profile in gallbladder cancer. J Gastroenterol. 2006;41(3):269\u2013275.","journal-title":"J Gastroenterol"},{"key":"4349_CR72","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1002\/mc.20457","volume":"48","author":"P Garc\u00eda","year":"2009","unstructured":"Garc\u00eda P, et al. Promoter methylation profile in preneoplastic and neoplastic gallbladder lesions. Mol Carcinog. 2009;48:79\u201389.","journal-title":"Mol Carcinog"},{"key":"4349_CR73","doi-asserted-by":"publisher","first-page":"882","DOI":"10.1245\/ASO.2003.02.014","volume":"10","author":"MG House","year":"2003","unstructured":"House MG, et al. Progression of gene hypermethylation in gallstone disease leading to gallbladder cancer. Ann Surg Oncol. 2003;10:882\u2013889.","journal-title":"Ann Surg Oncol"},{"issue":"8","key":"4349_CR74","doi-asserted-by":"publisher","first-page":"1309","DOI":"10.1111\/cts.13548","volume":"16","author":"AB Kagan","year":"2023","unstructured":"Kagan AB, et al. DNA methyltransferase inhibitor exposure-response: Challenges and opportunities. Clin Transl Sci. 2023;16(8):1309\u20131322.","journal-title":"Clin Transl Sci"},{"key":"4349_CR75","doi-asserted-by":"publisher","first-page":"176","DOI":"10.1186\/s12943-019-1109-9","volume":"18","author":"L He","year":"2019","unstructured":"He L, Li H, Wu A, et al. Functions of N6-methyladenosine and its role in cancer. Mol Cancer. 2019;18:176.","journal-title":"Mol Cancer"},{"key":"4349_CR76","doi-asserted-by":"publisher","first-page":"e70764","DOI":"10.1111\/jcmm.70764","volume":"29","author":"Y Liu","year":"2025","unstructured":"Liu Y, et al. Dysregulated RNA m6A Methylation Contributes to the Metastasis of Gallbladder Cancer Through miR-146a-5p. J Cell Mol Med. 2025;29:e70764.","journal-title":"J Cell Mol Med"},{"issue":"11","key":"4349_CR77","doi-asserted-by":"publisher","first-page":"4299","DOI":"10.1111\/cas.15953","volume":"114","author":"X Bai","year":"2023","unstructured":"Bai X, et al. YTHDF2 promotes gallbladder cancer progression and gemcitabine resistance via m6A-dependent DAPK3 degradation. Cancer Sci. 2023;114(11):4299\u20134313.","journal-title":"Cancer Sci"},{"key":"4349_CR78","doi-asserted-by":"publisher","first-page":"101764","DOI":"10.1016\/j.tranon.2023.101764","volume":"37","author":"J Qin","year":"2023","unstructured":"Qin J, et al. IGF2BP3 drives gallbladder cancer progression by m6A-modified CLDN4 and inducing macrophage immunosuppressive polarization. Transl Oncol. 2023;37:101764.","journal-title":"Transl Oncol"},{"key":"4349_CR79","doi-asserted-by":"publisher","first-page":"22","DOI":"10.3892\/ijmm.2024.5463","volume":"55","author":"L Zhang","year":"2025","unstructured":"Zhang L, et al. Role of the m6A demethylase ALKBH5 in gastrointestinal tract cancer (Review). Int J Mol Med. 2025;55:22.","journal-title":"Int J Mol Med"},{"key":"4349_CR80","doi-asserted-by":"publisher","first-page":"422","DOI":"10.1038\/s41419-024-06800-9","volume":"15","author":"Z Wu","year":"2024","unstructured":"Wu Z, Ke Q, Jiang L, et al. TGF-\u03b21 facilitates gallbladder carcinoma metastasis by regulating FOXA1 translation efficiency through m6A modification. Cell Death Dis. 2024;15:422.","journal-title":"Cell Death Dis"},{"issue":"4","key":"4349_CR81","doi-asserted-by":"publisher","first-page":"468","DOI":"10.1016\/j.intimp.2012.05.016","volume":"13","author":"Y Su","year":"2012","unstructured":"Su Y, et al. Aberrant expression of microRNAs in gastric cancer and biological significance of miR-574-3p. Int Immunopharmacol. 2012;13(4):468\u2013475.","journal-title":"Int Immunopharmacol"},{"key":"4349_CR82","doi-asserted-by":"publisher","first-page":"1100","DOI":"10.1177\/1947601910396213","volume":"1","author":"BN Davis-Dusenbery","year":"2010","unstructured":"Davis-Dusenbery BN, Hata A. MicroRNA in Cancer: The Involvement of Aberrant MicroRNA Biogenesis Regulatory Pathways. Genes Cancer. 2010;1:1100\u20131114.","journal-title":"Genes Cancer"},{"key":"4349_CR83","doi-asserted-by":"publisher","first-page":"15004","DOI":"10.1038\/sigtrans.2015.4","volume":"1","author":"Y Peng","year":"2016","unstructured":"Peng Y, Croce C. The role of MicroRNAs in human cancer. Sig Transduct Target Ther. 2016;1:15004.","journal-title":"Sig Transduct Target Ther"},{"key":"4349_CR84","doi-asserted-by":"publisher","first-page":"R762","DOI":"10.1016\/j.cub.2014.06.043","volume":"24","author":"D Brian","year":"2014","unstructured":"Brian D, Adams AL, Kasinski, Frank J. Slack. Aberrant Regulation and Function of MicroRNAs in Cancer. Curr Biol. 2014;24:R762\u2013R776.","journal-title":"Curr Biol"},{"key":"4349_CR85","doi-asserted-by":"publisher","first-page":"188","DOI":"10.1186\/s12967-022-03394-8","volume":"20","author":"J Cao","year":"2022","unstructured":"Cao J, Shao H, Hu J, et al. Identification of invasion-metastasis associated MiRNAs in gallbladder cancer by bioinformatics and experimental validation. J Transl Med. 2022;20:188. .","journal-title":"J Transl Med"},{"issue":"2","key":"4349_CR86","first-page":"49","volume":"5","author":"K Verma","year":"2020","unstructured":"Verma K, et al. Molecular genetics changes in gallbladder carcinoma. Int J Mol Immuno Oncol. 2020;5(2):49\u201361.","journal-title":"Int J Mol Immuno Oncol"},{"key":"4349_CR87","doi-asserted-by":"publisher","first-page":"716","DOI":"10.1016\/j.omtm.2020.11.019","volume":"20","author":"K Cui","year":"2021","unstructured":"Cui K, Bian X. The microRNA cluster miR-30b\/-30d prevents tumor cell switch from an epithelial to a mesenchymal-like phenotype in GBC. Mol Therapy - Methods Clin Dev. 2021;20:716\u201325.","journal-title":"Mol Therapy - Methods Clin Dev"},{"key":"4349_CR88","doi-asserted-by":"publisher","first-page":"240","DOI":"10.1186\/s12920-023-01663-z","volume":"16","author":"H Shao","year":"2023","unstructured":"Shao H, et al. Identification of characteristic genes and construction of regulatory network in gallbladder carcinoma. BMC Med Genomics. 2023;16:240. .","journal-title":"BMC Med Genomics"},{"key":"4349_CR89","doi-asserted-by":"publisher","first-page":"19101","DOI":"10.1038\/s41598-023-44767-3","volume":"13","author":"R Saxena","year":"2023","unstructured":"Saxena R, Chakrapani B, Krishnan S. Next generation sequencing uncovers multiple miRNAs associated molecular targets in gallbladder cancer patients. Sci Rep. 2023;13:19101. .","journal-title":"Sci Rep"},{"issue":"4","key":"4349_CR90","doi-asserted-by":"publisher","first-page":"69","DOI":"10.61186\/ijbc.16.4.69","volume":"16","author":"N Fatima","year":"2024","unstructured":"Fatima N, Raza ST, Kumar V, Rizvi S, Khan F. The Potential Role of microRNAs in the Progression and Aggressiveness of Gallbladder Cancer: Molecular Markers to Therapeutic Interventions. Iran J Blood Cancer. 2024;16(4):69\u201385.","journal-title":"Iran J Blood Cancer"},{"key":"4349_CR91","doi-asserted-by":"crossref","unstructured":"Zhang, J., et al. MicroRNA-182 promotes epithelial-mesenchymal transition by targeting FOXN3 in gallbladder cancer. Oncology Letters. 2021;21(3):20.","DOI":"10.3892\/ol.2021.12461"},{"key":"4349_CR92","first-page":"2448","volume":"6","author":"Y Huang","year":"2016","unstructured":"Huang Y, et al. MicroRNA-133a-3p exerts inhibitory effects on gallbladder carcinoma via targeting RBPJ. Am J Cancer Res. 2016;6:2448\u20132462.","journal-title":"Am J Cancer Res"},{"key":"4349_CR93","doi-asserted-by":"publisher","first-page":"e195","DOI":"10.1038\/mtna.2014.47","volume":"3","author":"G Misso","year":"2014","unstructured":"Misso G, et al. Mir-34: A New Weapon Against Cancer? Mol Therapy - Nucleic Acids. 2014;3:e195.","journal-title":"Mol Therapy - Nucleic Acids"},{"key":"4349_CR94","doi-asserted-by":"publisher","first-page":"5287","DOI":"10.2174\/1381612820666140128213117","volume":"20","author":"M Macha","year":"2014","unstructured":"Macha M, et al. MicroRNAs (mirnas) as biomarker(s) for prognosis and diagnosis of gastrointestinal (GI) cancers. Curr Pharm Design. 2014;20:5287\u20135297.","journal-title":"Curr Pharm Design"},{"key":"4349_CR95","doi-asserted-by":"publisher","first-page":"92","DOI":"10.1186\/s12935-015-0247-4","volume":"15","author":"AV Das","year":"2015","unstructured":"Das AV, Pillai RM. Implications of miR cluster 143\/145 as universal anti-oncomiRs and their dysregulation during tumorigenesis. Cancer Cell Int. 2015;15:92. .","journal-title":"Cancer Cell Int"},{"key":"4349_CR96","doi-asserted-by":"publisher","first-page":"5638","DOI":"10.1002\/cam4.2489","volume":"8","author":"X Jia","year":"2019","unstructured":"Jia X, Wang X, Guo X, et al. MicroRNA-124: An emerging therapeutic target in cancer. Cancer Med. 2019;8:5638\u20135650. .","journal-title":"Cancer Med"},{"key":"4349_CR97","doi-asserted-by":"publisher","first-page":"2941","DOI":"10.18632\/aging.202444","volume":"13","author":"B Zhang","year":"2021","unstructured":"Zhang B, Cui H, Sun Y, Wang X, Jia Q, Li J, Yin Y, Sun X, Xu H, Li H, Xu F, Rong J. Up-regulation of miR-204 inhibits proliferation, invasion and apoptosis of gallbladder cancer cells by targeting Notch2. Aging. 2021;13:2941\u20132958. .","journal-title":"Aging"},{"key":"4349_CR98","doi-asserted-by":"publisher","first-page":"2855","DOI":"10.2147\/OTT.S234549","volume":"13","author":"J Kong","year":"2020","unstructured":"Kong J, Wang W. A Systemic Review on the Regulatory Roles of miR-34a in Gastrointestinal Cancer. Onco Targets Ther. 2020;13:2855\u20132872.","journal-title":"Onco Targets Ther"},{"key":"4349_CR99","doi-asserted-by":"crossref","unstructured":"Chaeichi-Tehrani N, Gordon A, Hassanian SM, Khazaei M, Avan A. The Therapeutic Potential of Targeting Autophagy in the Treatment of Cancer.Current Cancer Drug Targets. 2021;21(9):725-736.","DOI":"10.2174\/1568009621666210601113144"},{"key":"4349_CR100","doi-asserted-by":"publisher","first-page":"4796","DOI":"10.1038\/s41598-019-40857-3","volume":"9","author":"B Goeppert","year":"2019","unstructured":"Goeppert B, et al. Profiling of gallbladder carcinoma reveals distinct miRNA profiles and activation of STAT1 by the tumor suppressive miRNA-145-5p. Sci Rep. 2019;9:4796.","journal-title":"Sci Rep"},{"key":"4349_CR101","doi-asserted-by":"publisher","first-page":"7","DOI":"10.3892\/mco.2016.905","volume":"5","author":"G Yang","year":"2016","unstructured":"Yang G, Zhang L, Li R, Wang L. The role of microRNAs in gallbladder cancer (Review). Mol Clin Oncol. 2016;5:7\u201313.","journal-title":"Mol Clin Oncol"},{"issue":"1","key":"4349_CR102","doi-asserted-by":"publisher","first-page":"84","DOI":"10.1016\/j.jhep.2012.01.018","volume":"57","author":"T Kitamura","year":"2012","unstructured":"Kitamura T, et al. The therapeutic effect of histone deacetylase inhibitor PCI-24781 on gallbladder carcinoma in BK5.erbB2 mice. J Hepatol. 2012;57(1):84\u201391.","journal-title":"J Hepatol"},{"key":"4349_CR103","doi-asserted-by":"publisher","first-page":"294","DOI":"10.1016\/j.biopha.2018.11.016","volume":"110","author":"P Lv","year":"2019","unstructured":"Lv P, et al. Long non-coding RNA SNHG6 enhances cell proliferation, migration and invasion by regulating miR-26a-5p\/MAPK6 in breast cancer. Biomed Pharmacother. 2019;110:294\u2013301.","journal-title":"Biomed Pharmacother"},{"key":"4349_CR104","doi-asserted-by":"publisher","first-page":"154320","DOI":"10.1016\/j.prp.2023.154320","volume":"242","author":"P Srivastava","year":"2023","unstructured":"Srivastava P, Mishra S, Agarwal A, Pandey A, Husain N. Circulating microRNAs in gallbladder cancer: Is serum assay of diagnostic value? Pathol - Res Pract. 2023;242:154320.","journal-title":"Pathol - Res Pract"},{"issue":"8","key":"4349_CR105","doi-asserted-by":"publisher","first-page":"956","DOI":"10.1111\/cas.12463","volume":"105","author":"H Zhou","year":"2014","unstructured":"Zhou H, et al. Micro\u2009<\u2009scp>RNA-135a acts as a putative tumor suppressor by directly targeting very low density lipoprotein receptor in human gallbladder cancer. Cancer Sci. 2014;105(8):956\u2013965.","journal-title":"Cancer Sci"},{"key":"4349_CR106","doi-asserted-by":"publisher","first-page":"2050","DOI":"10.3892\/ijo.2014.2360","volume":"44","author":"H ZHOU","year":"2014","unstructured":"Zhou H, et al. MicroRNA-26a acts as a tumor suppressor inhibiting gallbladder cancer cell proliferation by directly targeting HMGA2. Int J Oncol. 2014;44:2050\u20132058.","journal-title":"Int J Oncol"},{"key":"4349_CR107","doi-asserted-by":"crossref","unstructured":"Zhang Y, Peng H, Zhang Y, Gong L, Liu W. Increased expression of microRNA-335 predicts a favorable prognosis in primary gallbladder carcinoma. OTT. 2013; 6:1625-1630.","DOI":"10.2147\/OTT.S53030"},{"key":"4349_CR108","doi-asserted-by":"publisher","first-page":"e1583","DOI":"10.1038\/cddis.2014.541","volume":"6","author":"M-Z Ma","year":"2015","unstructured":"Ma M-Z, et al. Long non-coding RNA CCAT1 promotes gallbladder cancer development via negative modulation of miRNA-218-5p. Cell Death Dis. 2015;6:e1583\u20131583.","journal-title":"Cell Death Dis"},{"key":"4349_CR109","doi-asserted-by":"publisher","first-page":"17","DOI":"10.3892\/or.2013.2443","volume":"30","author":"H KONO","year":"2013","unstructured":"Kono H, et al. High expression of microRNA-155 is associated with the aggressive malignant behavior of gallbladder carcinoma. Oncol Rep. 2013;30:17\u201324.","journal-title":"Oncol Rep"},{"key":"4349_CR110","doi-asserted-by":"publisher","first-page":"518","DOI":"10.1016\/j.jhep.2013.04.034","volume":"59","author":"Y Chang","year":"2013","unstructured":"Chang Y, et al. miR-20a triggers metastasis of gallbladder carcinoma. J Hepatol. 2013;59:518\u2013527.","journal-title":"J Hepatol"},{"key":"4349_CR111","doi-asserted-by":"publisher","first-page":"154684","DOI":"10.1016\/j.prp.2023.154684","volume":"248","author":"RK Shahin","year":"2023","unstructured":"Shahin RK, et al. miRNAs orchestration of gallbladder cancer \u2013 Particular emphasis on diagnosis, progression and drug resistance. Pathol - Res Pract. 2023;248:154684.","journal-title":"Pathol - Res Pract"},{"issue":"2","key":"4349_CR112","first-page":"49","volume":"5","author":"K Verma","year":"2020","unstructured":"Verma K, et al. Molecular genetics changes in gallbladder carcinoma. Int J Mol Immuno Oncol. 2020;5(2):49\u201361.","journal-title":"Int J Mol Immuno Oncol"},{"key":"4349_CR113","doi-asserted-by":"publisher","first-page":"96","DOI":"10.1038\/s41580-020-00315-9","volume":"22","author":"L Statello","year":"2021","unstructured":"Statello L, Guo CJ, Chen LL, et al. Gene regulation by long non-coding RNAs and its biological functions. Nat Rev Mol Cell Biol. 2021;22:96\u2013118.","journal-title":"Nat Rev Mol Cell Biol"},{"key":"4349_CR114","first-page":"36","volume":"7","author":"V Aliperti","year":"2021","unstructured":"Aliperti V, Skonieczna J, Cerase A. Long Non-Coding RNA (lncRNA) Roles in Cell Biology, Neurodevelopment and Neurological Disorders. Noncoding RNA. 2021;7:36.","journal-title":"Noncoding RNA"},{"issue":"3","key":"4349_CR115","doi-asserted-by":"publisher","first-page":"254","DOI":"10.1093\/bfgp\/elt016","volume":"12","author":"PP Amaral","year":"2013","unstructured":"Amaral PP, Dinger ME, Mattick JS. Non-coding RNAs in homeostasis, disease and stress responses: an evolutionary perspective. Brief Funct Genomics. 2013;12(3):254\u201378.","journal-title":"Brief Funct Genomics"},{"key":"4349_CR116","doi-asserted-by":"publisher","first-page":"169","DOI":"10.1186\/s12935-019-0891-1","volume":"19","author":"Y Zhong","year":"2019","unstructured":"Zhong Y, et al. Long noncoding RNAs as potential biomarkers and therapeutic targets in gallbladder cancer: a systematic review and meta-analysis. Cancer Cell Int. 2019;19:169.","journal-title":"Cancer Cell Int"},{"key":"4349_CR117","doi-asserted-by":"publisher","first-page":"9875","DOI":"10.1007\/s13277-016-4863-y","volume":"37","author":"B Liu","year":"2016","unstructured":"Liu B, et al. Expression and mechanisms of long non-coding RNA genes MEG3 and ANRIL in gallbladder cancer. Tumour Biol. 2016;37:9875\u20139886.","journal-title":"Tumour Biol"},{"key":"4349_CR118","doi-asserted-by":"publisher","first-page":"5466","DOI":"10.7150\/jca.46351","volume":"11","author":"S Liu","year":"2020","unstructured":"Liu S, et al. DGCR5 Promotes Gallbladder Cancer by Sponging MiR-3619-5p via MEK\/ERK1\/2 and JNK\/p38 MAPK Pathways. J Cancer. 2020;11:5466\u20135477.","journal-title":"J Cancer"},{"key":"4349_CR119","doi-asserted-by":"crossref","unstructured":"Lu L, Zhang S, Song Z, Lu W, Wang Z, Zhou Y. (2021) Long Non-Coding RNA LINC01410 Promoted Tumor Progression via the ErbB Signaling Pathway by Targeting STAT5 in Gallbladder Cancer. Front Oncol. 2021;11:659123.","DOI":"10.3389\/fonc.2021.659123"},{"issue":"10","key":"4349_CR120","doi-asserted-by":"publisher","first-page":"1837","DOI":"10.15252\/embr.201744147","volume":"18","author":"X-S Wu","year":"2017","unstructured":"Wu X-S, et al. LncRNA\u2010PAGBC acts as a microRNA sponge and promotes gallbladder tumorigenesis. EMBO Rep. 2017;18(10):1837-1853.","journal-title":"EMBO Rep"},{"key":"4349_CR121","doi-asserted-by":"publisher","first-page":"1017","DOI":"10.1038\/s41419-018-1064-1","volume":"9","author":"L Jin","year":"2018","unstructured":"Jin L, et al. Long noncoding RNA MEG3 regulates LATS2 by promoting the ubiquitination of EZH2 and inhibits proliferation and invasion in gallbladder cancer. Cell Death Dis. 2018;9:1017.","journal-title":"Cell Death Dis"},{"key":"4349_CR122","doi-asserted-by":"publisher","first-page":"167","DOI":"10.1186\/s12943-019-1097-9","volume":"18","author":"Y Hu","year":"2019","unstructured":"Hu Y, et al. LncRNA-HGBC stabilized by HuR promotes gallbladder cancer progression by regulating miR-502-3p\/SET\/AKT axis. Mol Cancer. 2019;18:167.","journal-title":"Mol Cancer"},{"key":"4349_CR123","doi-asserted-by":"publisher","first-page":"e201","DOI":"10.1002\/ctm2.201","volume":"10","author":"H Li","year":"2020","unstructured":"Li H, et al. Long noncoding RNA lncGALM increases risk of liver metastasis in gallbladder cancer through facilitating N-cadherin and IL-1\u03b2-dependent liver arrest and tumor extravasation. Clin Transl Med. 2020;10:e201.","journal-title":"Clin Transl Med"},{"key":"4349_CR124","doi-asserted-by":"publisher","first-page":"124","DOI":"10.1016\/j.omto.2021.08.016","volume":"23","author":"J Bohao Zheng","year":"2021","unstructured":"Bohao Zheng J, Wang K, Sun FW, Wan W, Gao Z, Ni X, Zhang D, Ni X, Suo T, Liu H, Liu H. Sheng Shen. lncRNA RP11-147L13.8 suppresses metastasis and chemo-resistance by modulating the phosphorylation of c-Jun protein in GBC. Mol Therapy - Oncolytics. 2021;23:124\u2013137.","journal-title":"Mol Therapy - Oncolytics"},{"key":"4349_CR125","first-page":"2583","volume":"9","author":"P Sridhar Mishra","year":"2024","unstructured":"Sridhar Mishra P, Srivastava A, Pandey A, Agarwal S, Shukla N, Husain. Panel of serum long non-coding RNAs as potential non-invasive biomarkers for gallbladder carcinoma. Non-coding RNA Res. 2024;9(2):583\u2013593.","journal-title":"Non-coding RNA Res"},{"key":"4349_CR126","doi-asserted-by":"publisher","first-page":"100563","DOI":"10.1016\/j.aohep.2021.100563","volume":"26","author":"C Fu","year":"2021","unstructured":"Fu C, Nie L, Yin T, Xu X, Lu W. LncRNA EPIC1 promotes proliferation and inhibits apoptosis of gallbladder cancer cells by interacting with LET. Ann Hepatol. 2021;26:100563.","journal-title":"Ann Hepatol"},{"key":"4349_CR127","doi-asserted-by":"publisher","first-page":"152","DOI":"10.1016\/j.biochi.2016.11.007","volume":"132","author":"A Khandelwal","year":"2016","unstructured":"Khandelwal A, Malhotra A, Jain M, Vasquez KM, Jain A. The emerging role of long non-coding RNA in gallbladder cancer pathogenesis. Biochimie. 2016;132:152\u2013160.","journal-title":"Biochimie"},{"key":"4349_CR128","doi-asserted-by":"publisher","first-page":"167","DOI":"10.1186\/s12943-019-1097-9","volume":"18","author":"Y Hu","year":"2019","unstructured":"Hu Y, et al. LncRNA-HGBC stabilized by HuR promotes gallbladder cancer progression by regulating miR-502-3p\/SET\/AKT axis. Mol Cancer. 2019;18:167.","journal-title":"Mol Cancer"},{"key":"4349_CR129","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1038\/358015a0","volume":"358","author":"D Lane","year":"1992","unstructured":"Lane D. p53, guardian of the genome. Nature. 1992;358:15\u201316.","journal-title":"Nature"},{"key":"4349_CR130","doi-asserted-by":"publisher","first-page":"174","DOI":"10.1080\/13651820410025110","volume":"6","author":"LA Hidao Grau","year":"2004","unstructured":"Hidao Grau LA, et al. Gallbladder carcinoma: the role of p53 protein overexpression and Ki-67 antigen expression as prognostic markers. HPB (Oxford). 2004;6:174\u2013180.","journal-title":"HPB (Oxford)"},{"key":"4349_CR131","first-page":"1062","volume":"170:6","author":"R Edward","year":"2017","unstructured":"Edward R, Kastenhuber, Scott W. Lowe.Putting p53 inContext. Cell. 2017;170:6:1062\u20131078.","journal-title":"Context Cell"},{"key":"4349_CR132","doi-asserted-by":"crossref","unstructured":"Liz J, Hern\u00e1ndez Borrero WS. El-Deiry.Tumor suppressor p53: Biology, signaling pathways, and therapeutic targeting.Biochimica et Biophysica Acta (BBA) - Reviews on Cancer.2021,1876(1):188556","DOI":"10.1016\/j.bbcan.2021.188556"},{"key":"4349_CR133","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1111\/j.1365-2249.2010.04163.x","volume":"161","author":"H Igarashi","year":"2010","unstructured":"Igarashi H, Hashimoto J, Tomita T, Yoshikawa H, Ishihara K. TP53 mutations coincide with the ectopic expression of activation-induced cytidine deaminase in the fibroblast-like synoviocytes derived from a fraction of patients with rheumatoid arthritis. Clin Exp Immunol. 2010;161:71\u201380.","journal-title":"Clin Exp Immunol"},{"key":"4349_CR134","doi-asserted-by":"publisher","first-page":"1542","DOI":"10.1002\/1097-0142(19940901)74:5<1542::AID-CNCR2820740508>3.0.CO;2-U","volume":"74","author":"M Teh","year":"1994","unstructured":"Teh M, Wee A, Raju GC. An immunohistochemical study of p53 protein in gallbladder and extrahepatic bile duct\/ampullary carcinomas. Cancer. 1994;74:1542\u20131545.","journal-title":"Cancer"},{"key":"4349_CR135","first-page":"1127","volume":"8","author":"YW Kim","year":"2001","unstructured":"Kim YW, et al. Expression of the c-erb-B2 and p53 protein in gallbladder carcinomas. Oncol Rep. 2001;8:1127\u20131132.","journal-title":"Oncol Rep"},{"key":"4349_CR136","doi-asserted-by":"publisher","first-page":"34","DOI":"10.4103\/1319-3767.105922","volume":"19","author":"M Ghosh","year":"2013","unstructured":"Ghosh M, Sakhuja P, Singh S, Agarwal AK. p53 and beta-catenin expression in gallbladder tissues and correlation with tumor progression in gallbladder cancer. Saudi J Gastroenterol. 2013;19:34\u201339.","journal-title":"Saudi J Gastroenterol"},{"key":"4349_CR137","doi-asserted-by":"publisher","first-page":"1523","DOI":"10.1055\/s-0028-1106415","volume":"100","author":"M Barthels","year":"1975","unstructured":"Barthels M, Gerstel J. [Joint bleeding in haemophiliacs receiving substitution treatment as out-patients (author\u2019s transl)]. Dtsch Med Wochenschr. 1975;100:1523\u20131529.","journal-title":"Dtsch Med Wochenschr"},{"key":"4349_CR138","first-page":"3192","volume":"4","author":"M Moreno","year":"2005","unstructured":"Moreno M, Pimentel F, Gazdar AF, Wistuba II. Miquel.TP53 Abnormalities are frequent and early events in the sequential pathogenesis of gallbladder carcinoma\u00a7. Original Article Annals Hepatol. 2005;4:3192\u20133199.","journal-title":"Original Article Annals Hepatol"},{"key":"4349_CR139","doi-asserted-by":"publisher","first-page":"333","DOI":"10.1111\/j.1440-1827.1996.tb03618.x","volume":"46","author":"T Itoi","year":"1996","unstructured":"Itoi T, et al. APC, K-ras codon 12 mutations and p53 gene expression in carcinoma and adenoma of the gall-bladder suggest two genetic pathways in gall-bladder carcinogenesis. Pathol Int. 1996;46:333\u2013340.","journal-title":"Pathol Int"},{"key":"4349_CR140","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1016\/S0046-8177(99)90295-2","volume":"30","author":"II Wistuba","year":"1999","unstructured":"Wistuba II, Miquel JF, Gazdar AF, Albores-Saavedra J. Gallbladder adenomas have molecular abnormalities different from those present in gallbladder carcinomas. Hum Pathol. 1999;30:21\u201325.","journal-title":"Hum Pathol"},{"key":"4349_CR141","doi-asserted-by":"crossref","unstructured":"Qin J-J, Li X, Hunt C, Wang W, Wang, Hui, Zhang, Ruiwen. Natural products targeting the p53-MDM2 pathway and mutant p53: Recent advances and implications in cancer medicine. Genes Dis. 2018;5(3):204-219.","DOI":"10.1016\/j.gendis.2018.07.002"},{"key":"4349_CR142","doi-asserted-by":"publisher","first-page":"5599","DOI":"10.3390\/cancers13225599","volume":"13","author":"HJ Kim","year":"2021","unstructured":"Kim HJ, Lee HN, Jeong MS, Jang SB, Oncogenic KRAS. Signaling and Drug Resistance. Cancers (Basel). 2021;13:5599.","journal-title":"Cancers (Basel)"},{"issue":"4","key":"4349_CR143","doi-asserted-by":"publisher","first-page":"375","DOI":"10.1016\/S1535-6108(04)00085-6","volume":"5","author":"DA Tuveson","year":"2004","unstructured":"Tuveson DA, et al. Endogenous oncogenic K-rasG12D stimulates proliferation and widespread neoplastic and developmental defects. Cancer Cell. 2004;5(4):375\u2013387.","journal-title":"Cancer Cell"},{"issue":"12","key":"4349_CR144","first-page":"2511","volume":"55","author":"I Ignacio","year":"1995","unstructured":"Ignacio I, et al. Gazdar; Allele-specific Mutations Involved in the Pathogenesis of Endemic Gallbladder Carcinoma in Chile. Cancer Res. 1995;55(12):2511\u20132515.","journal-title":"Cancer Res 15 June"},{"key":"4349_CR145","doi-asserted-by":"publisher","first-page":"2183","DOI":"10.3390\/cells11142183","volume":"11","author":"A Ferreira","year":"2022","unstructured":"Ferreira A, et al. Crucial Role of Oncogenic KRAS Mutations in Apoptosis and Autophagy Regulation: Therapeutic Implications. Cells. 2022;11:2183.","journal-title":"Cells"},{"key":"4349_CR146","first-page":"17","volume":"1","author":"R Julian","year":"2006","unstructured":"Julian R, Molina AA. Adjei.The Ras\/Raf\/MAPK Pathway. J Thorac Oncol. 2006;1:17\u201319.","journal-title":"J Thorac Oncol"},{"key":"4349_CR147","doi-asserted-by":"publisher","first-page":"954","DOI":"10.18632\/oncotarget.652","volume":"3","author":"J McCubrey","year":"2012","unstructured":"McCubrey JA, et al. Mutations and deregulation of Ras\/Raf\/MEK\/ERK and PI3K\/PTEN\/Akt\/mTOR cascades which alter therapy response. Oncotarget. 2012;3(9):954-987.","journal-title":"Therapy Response Oncotarget"},{"key":"4349_CR148","doi-asserted-by":"publisher","first-page":"159","DOI":"10.1016\/S0304-3835(01)00562-6","volume":"169","author":"J Kim","year":"2001","unstructured":"Kim J, et al. Genetic alterations in gallbladder adenoma. dysplasia and carcinoma. Cancer Lett. 2001;169:159\u2013168.","journal-title":"Cancer Lett"},{"key":"4349_CR149","doi-asserted-by":"publisher","first-page":"532","DOI":"10.1016\/S0344-0338(96)80102-6","volume":"192","author":"A Saetta","year":"1996","unstructured":"Saetta A, Lazaris AC, Davaris PS. Detection of Ras Oncogene Point Mutations and Simultaneous Proliferative Fraction Estimation in Gallbladder Cancer. Pathol - Res Pract. 1996;192(6):532\u2013540.","journal-title":"Pathol - Res Pract"},{"issue":"6","key":"4349_CR150","doi-asserted-by":"publisher","first-page":"1638","DOI":"10.1111\/j.1572-0241.1999.01155.x","volume":"94","author":"A Keiji Hanada","year":"1999","unstructured":"Keiji Hanada A, et al. Goro Kajiyama. Gene mutations of K-ras in gallbladder mucosae and gallbladder carcinoma with an anomalous junction of the pancreaticobiliary duct. Am J Gastroenterol. 1999;94(6):1638\u20131642.","journal-title":"Am J Gastroenterol"},{"key":"4349_CR151","doi-asserted-by":"publisher","first-page":"1752","DOI":"10.1002\/(SICI)1097-0142(19960415)77:8<1752::AID-CNCR51>3.0.CO;2-V","volume":"77","author":"T Matsubara","year":"1996","unstructured":"Matsubara T, et al. K-ras point mutations in cancerous and noncancerous biliary epithelium in patients with pancreaticobiliary maljunction. Cancer. 1996;77:1752\u20131757.","journal-title":"Cancer"},{"key":"4349_CR152","doi-asserted-by":"publisher","first-page":"4088","DOI":"10.1200\/JCO.2023.41.16_suppl.4088","volume":"41","author":"M Gordon Taylor","year":"2023","unstructured":"Gordon Taylor M, et al. Characterizing KRAS allele variants within biliary tract cancers. JCO. 2023;41:4088\u20134088.","journal-title":"JCO"},{"key":"4349_CR153","doi-asserted-by":"publisher","first-page":"44299","DOI":"10.18632\/oncotarget.9996","volume":"7","author":"T Pan","year":"2016","unstructured":"Pan T, et al. A recombinant chimeric protein specifically induces mutant KRAS degradation and potently inhibits pancreatic tumor growth. Oncotarget. 2016;7:44299\u201344309.","journal-title":"Oncotarget"},{"issue":"4","key":"4349_CR154","doi-asserted-by":"publisher","first-page":"913","DOI":"10.1158\/2159-8290.CD-22-0035","volume":"12","author":"C Johnson","year":"2022","unstructured":"Johnson C, Burkhart DL, Haigis KM. Classification of KRAS-Activating Mutations and the Implications for Therapeutic Intervention. Cancer Discov. 2022;12(4):913\u2013923.","journal-title":"Cancer Discov"},{"key":"4349_CR155","doi-asserted-by":"crossref","unstructured":"Kumar M, Kumar A, Srivastav A, Ghosh A, Kumar D. Genomic and molecular landscape of gallbladder cancer elucidating pathogenic mechanisms novel therapeutic targets and clinical implications. Mutation Research - Fundamental and Molecular Mechanisms of Mutagenesis. 2025;830:111896.","DOI":"10.1016\/j.mrfmmm.2024.111896"},{"key":"4349_CR156","doi-asserted-by":"publisher","first-page":"6630","DOI":"10.18632\/oncotarget.23553","volume":"9","author":"M Del Re","year":"2018","unstructured":"Del Re M, et al. Implications of KRAS mutations in acquired resistance to treatment in NSCLC. Oncotarget. 2018;9:6630\u20136643.","journal-title":"Oncotarget"},{"key":"4349_CR157","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1007\/s10555-025-10243-9","volume":"44","author":"Y Wang","year":"2025","unstructured":"Wang Y, Bui TA, Yang X, Hutvagner G, Deng W. Advancements in gene therapies targeting mutant KRAS in cancers. Cancer Metastasis Rev. 2025;44:24.","journal-title":"Cancer Metastasis Rev"},{"key":"4349_CR158","doi-asserted-by":"crossref","unstructured":"Little AS, et al . A correction to the Research Article titled: Amplification of the driving oncogene, KRAS or BRAF, underpins acquired resistance to MEK1\/2 inhibitors in colorectal cancer cells. Sci. Signal. 2011;4(170):er2.","DOI":"10.1126\/scisignal.2001752"},{"key":"4349_CR159","doi-asserted-by":"publisher","first-page":"159","DOI":"10.1186\/s12943-022-01629-2","volume":"21","author":"C Zhu","year":"2022","unstructured":"Zhu C, et al. Targeting KRAS mutant cancers: from druggable therapy to drug resistance. Mol Cancer. 2022;21:159.","journal-title":"Mol Cancer"},{"key":"4349_CR160","doi-asserted-by":"publisher","first-page":"386","DOI":"10.1038\/s41392-021-00780-4","volume":"6","author":"L Huang","year":"2021","unstructured":"Huang L, et al. KRAS mutation: from undruggable to druggable in cancer. Sig Transduct Target Ther. 2021;6:386.","journal-title":"Sig Transduct Target Ther"},{"key":"4349_CR161","doi-asserted-by":"publisher","first-page":"6115","DOI":"10.1038\/sj.onc.1203972","volume":"19","author":"D Yu","year":"2000","unstructured":"Yu D, Hung MC. Overexpression of ErbB2 in cancer and ErbB2-targeting strategies. Oncogene. 2000;19:6115\u20136121.","journal-title":"Oncogene"},{"key":"4349_CR162","doi-asserted-by":"crossref","unstructured":"Nas G, Yasar T, Gunduz M, Gunduz E. Biomarkers in Endometrial Cancer. Noninvasive Molecular Markers in Gynecologic Cancers, CRC Press. 2015;1:408\u2013423.","DOI":"10.1201\/b18015-20"},{"issue":"4","key":"4349_CR163","doi-asserted-by":"publisher","first-page":"F577","DOI":"10.1152\/ajprenal.00607.2016","volume":"312","author":"AJ Streets","year":"2017","unstructured":"Streets AJ, Magayr TA, Huang L, Vergoz L, Rossetti S, Simms RJ, Harris PC, Peters DJM, Ong AC. M. Parallel microarray profiling identifies ErbB4 as a determinant of cyst growth in ADPKD and a prognostic biomarker for disease progression. AJP Ren Physiol. 2017;312(4):F577\u2013F588.","journal-title":"AJP Ren Physiol"},{"key":"4349_CR164","doi-asserted-by":"crossref","unstructured":"Hanrahan AJ, Iyer G, Solit DB. Intracellular signaling Abeloff's Clinical Oncology (Sixth Edition). Elsevier. 2020; 24-46.","DOI":"10.1016\/B978-0-323-47674-4.00002-5"},{"issue":"6","key":"4349_CR165","doi-asserted-by":"publisher","first-page":"7239","DOI":"10.1007\/s13277-015-4609-2","volume":"37","author":"R Watrowski","year":"2016","unstructured":"Watrowski R, et al. Association of HER2 codon 655 polymorphism with ovarian cancer. Tumour Biol. 2016;37(6):7239\u20137244.","journal-title":"Tumour Biol"},{"key":"4349_CR166","doi-asserted-by":"publisher","first-page":"4011","DOI":"10.1200\/jco.2006.24.18_suppl.4011","volume":"24","author":"T Kawamoto","year":"2006","unstructured":"Kawamoto T, et al. Amplification of HER-2\/neu (erbB2) gene expression in gallbladder (GBC) and in bile duct cancer (BDC) (biliary tract cancer, BTC). JCO. 2006;24(18):4011.","journal-title":"JCO"},{"key":"4349_CR167","doi-asserted-by":"crossref","unstructured":"Mondaca S et al. Genomic Characterization of ERBB2-Driven Biliary Cancer and a Case of Response to Ado-Trastuzumab Emtansine. JCO Precis Oncol. 2019,3:pp1-9.","DOI":"10.1200\/PO.19.00223"},{"issue":"8","key":"4349_CR168","doi-asserted-by":"publisher","first-page":"2008","DOI":"10.1002\/ijc.31916","volume":"144","author":"P Iyer","year":"2019","unstructured":"Iyer P, et al. ERBB2 and KRAS alterations mediate response to EGFR inhibitors in early stage gallbladder cancer. Int J Cancer. 2019;144(8):2008\u20132019.","journal-title":"Int J Cancer"},{"key":"4349_CR169","doi-asserted-by":"crossref","unstructured":"Li M, Liu F, Zhang F. Genomic ERBB2\/ERBB3 mutations promote PD-L1-mediated immune escape in gallbladder cancer: a whole-exome sequencing analysis.Gut 2019;6 :1024\u2013 1033.","DOI":"10.1136\/gutjnl-2018-316039"},{"issue":"8","key":"4349_CR170","doi-asserted-by":"publisher","first-page":"730","DOI":"10.1089\/hum.2014.006","volume":"25","author":"E Lanitis","year":"2014","unstructured":"Lanitis E, et al. A human ErbB2-specific T-cell receptor confers potent antitumor effector functions in genetically engineered primary cytotoxic lymphocytes. Hum Gene Ther. 2014;25(8):730\u2013739.","journal-title":"Hum Gene Ther"},{"key":"4349_CR171","doi-asserted-by":"publisher","first-page":"66","DOI":"10.1093\/nar\/gki145","volume":"33","author":"U Testa","year":"2005","unstructured":"Testa U, Pelosi E, Castelli G, Cholangiocarcinoma: MolecuPatsialou A, Wilsker D, Moran E. DNA-binding properties of ARID family proteins. Nucleic Acids Res. 2005;33:66\u201380.","journal-title":"Nucleic Acids Res"},{"key":"4349_CR172","first-page":"95","volume":"13","author":"D Wilsker","year":"2002","unstructured":"Wilsker D, Patsialou A, Dallas PB, Moran E. ARID proteins: a diverse family of DNA binding proteins implicated in the control of cell growth, differentiation, and development. Cell Growth Differ. 2002;13:95\u2013106.","journal-title":"Cell Growth Differ"},{"key":"4349_CR173","doi-asserted-by":"publisher","first-page":"3067","DOI":"10.1101\/gad.9.24.3067","volume":"9","author":"RF Herrscher","year":"1995","unstructured":"Herrscher RF, et al. The immunoglobulin heavy-chain matrix-associating regions are bound by Bright: a B cell-specific trans-activator that describes a new DNA-binding protein family. Genes Dev. 1995;9:3067\u20133082.","journal-title":"Genes Dev"},{"issue":"5","key":"4349_CR174","doi-asserted-by":"publisher","first-page":"235","DOI":"10.1002\/em.22087","volume":"58","author":"N Chatterjee","year":"2017","unstructured":"Chatterjee N, Walker GC. Mechanisms of DNA damage, repair, and mutagenesis. Environ Mol Mutagen. 2017;58(5):235\u2013263.","journal-title":"Environ Mol Mutagen"},{"key":"4349_CR175","doi-asserted-by":"publisher","first-page":"179","DOI":"10.1016\/j.molcel.2010.09.019","volume":"40","author":"A Ciccia","year":"2010","unstructured":"Ciccia A, Elledge SJ. The DNA damage response: making it safe to play with knives. Mol Cell. 2010;40:179\u2013204.","journal-title":"Mol Cell"},{"key":"4349_CR176","doi-asserted-by":"crossref","unstructured":"Zhang X, Zhang Y, Zhao J, Wu Y, Zhang N, Shen W. ARID1A mutations in cancer development: mechanism and therapy. Volume 44. Carcinogenesis. 2023. 44(3):197\u2013208.","DOI":"10.1093\/carcin\/bgad011"},{"key":"4349_CR177","doi-asserted-by":"crossref","unstructured":"Li J, Fu Y, Zhang H. Hong Ma.Molecular and pathological landscape of the AT-rich interaction domain 1A (ARID1A) mutation in hepatocellular carcinoma. Pathol - Res Pract,2025,266:155763 .","DOI":"10.1016\/j.prp.2024.155763"},{"issue":"7","key":"4349_CR178","doi-asserted-by":"publisher","first-page":"752","DOI":"10.1158\/2159-8290.CD-14-0849","volume":"5","author":"Y Jianfeng Shen","year":"2015","unstructured":"Jianfeng Shen Y, Peng L, Wei W, Zhang L, Yang L, Lan P, Kapoor Z, Ju Q, Mo I-M, Shih, Ivan P, Uray X, Wu PH, Brown X, Shen GB. Mills. Guang Peng; ARID1A Deficiency Impairs the DNA Damage Checkpoint and Sensitizes Cells to PARP Inhibitors. Cancer Discov. 2015;5(7):752\u2013767.","journal-title":"Cancer Discov"},{"issue":"10","key":"4349_CR179","doi-asserted-by":"publisher","first-page":"5698","DOI":"10.1093\/nar\/gkae233","volume":"52","author":"B Ali","year":"2024","unstructured":"Ali B, et al. ARID1A regulates DNA repair through chromatin organization and its deficiency triggers DNA damage-mediated anti-tumor immune response. Nucleic Acids Res. 2024;52(10):5698\u20135719.","journal-title":"Nucleic Acids Res"},{"issue":"3","key":"4349_CR180","doi-asserted-by":"publisher","first-page":"552","DOI":"10.1053\/jhep.2002.31774","volume":"35","author":"UC Nzeako","year":"2002","unstructured":"Nzeako UC, Guicciardi ME, Yoon JH, Bronk SF, Gores GJ. COX-2 inhibits Fas-mediated apoptosis in cholangiocarcinoma cells. Hepatology. 2002;35(3):552\u2013559.","journal-title":"Hepatology"},{"key":"4349_CR181","doi-asserted-by":"crossref","unstructured":"Testa U, Pelosi E, Castelli G. Cholangiocarcinoma: Molecular Abnormalities and Cells of Origin. Technol Cancer Res Treat. 2023 Jan-Dec;22:15330338221128689.","DOI":"10.1177\/15330338221128689"},{"issue":"24","key":"4349_CR182","first-page":"5359","volume":"15","author":"A Nicolas","year":"2022","unstructured":"Giraldo NA, et al. Comprehensive Molecular Characterization of Gallbladder Carcinoma and Potential Targets for Intervention. Clin Cancer Res. 2022;15(24):5359\u20135367.","journal-title":"Clin Cancer Res"},{"issue":"6","key":"4349_CR183","doi-asserted-by":"publisher","first-page":"815","DOI":"10.1093\/ajcp\/aqw071","volume":"145","author":"M Sasaki","year":"2016","unstructured":"Sasaki M, Nitta T, Sato Y, Nakanuma Y. Loss of ARID1A Expression Presents a Novel Pathway of Carcinogenesis in Biliary Carcinomas. Am J Clin Pathol. 2016;145(6):815\u2013825.","journal-title":"Am J Clin Pathol"},{"key":"4349_CR184","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1007\/s13304-020-00718-5","volume":"72","author":"S Conci","year":"2020","unstructured":"Conci S, et al. Multigene mutational profiling of biliary tract cancer is related to the pattern of recurrence in surgically resected patients. Updates Surg. 2020;72:119\u2013128.","journal-title":"Updates Surg"},{"issue":"24","key":"4349_CR185","doi-asserted-by":"publisher","first-page":"3838","DOI":"10.1002\/cncr.30254","volume":"122","author":"M Javle","year":"2016","unstructured":"Javle M, et al. Biliary cancer: Utility of next-generation sequencing for clinical management. Cancer. 2016;122(24):3838\u20133847.","journal-title":"Cancer"},{"key":"4349_CR186","doi-asserted-by":"publisher","first-page":"787897","DOI":"10.3389\/fonc.2022.787897","volume":"12","author":"L Nan","year":"2022","unstructured":"Nan L, et al. ARID1A Downregulation Predicts High PD-L1 Expression and Worse Clinical Outcome in Patients With Gallbladder Cancer. Front Oncol. 2022;12:787897.","journal-title":"Front Oncol"},{"issue":"3","key":"4349_CR187","doi-asserted-by":"publisher","first-page":"377","DOI":"10.1093\/carcin\/bgp014","volume":"30","author":"A Greenhough","year":"2009","unstructured":"Greenhough A, et al. The COX-2\/PGE2 pathway: key roles in the hallmarks of cancer and adaptation to the tumour microenvironment. Carcinogenesis. 2009;30(3):377\u2013386.","journal-title":"Carcinogenesis"},{"key":"4349_CR188","doi-asserted-by":"publisher","first-page":"106","DOI":"10.1186\/s12935-015-0260-7","volume":"15","author":"B Liu","year":"2015","unstructured":"Liu B, Qu L, Yan S. Cyclooxygenase-2 promotes tumor growth and suppresses tumor immunity. Cancer Cell Int. 2015;15:106.","journal-title":"Cancer Cell Int"},{"issue":"3","key":"4349_CR189","first-page":"961","volume":"9","author":"S Sharma","year":"2003","unstructured":"Sharma S, et al. Tumor cyclooxygenase 2-dependent suppression of dendritic cell function. Clin Cancer Res. 2003;9(3):961\u2013968.","journal-title":"Clin Cancer Res"},{"issue":"3","key":"4349_CR190","doi-asserted-by":"publisher","first-page":"289","DOI":"10.1038\/nm0302-289","volume":"8","author":"R Pai","year":"2002","unstructured":"Pai R, et al. Prostaglandin E2 transactivates EGF receptor: a novel mechanism for promoting colon cancer growth and gastrointestinal hypertrophy. Nat Med. 2002;8(3):289\u2013293.","journal-title":"Nat Med"},{"issue":"12","key":"4349_CR191","doi-asserted-by":"publisher","first-page":"1640","DOI":"10.1096\/fj.02-1011com","volume":"17","author":"R Pai","year":"2003","unstructured":"Pai R, Nakamura T, Moon WS, Tarnawski AS. Prostaglandins promote colon cancer cell invasion; signaling by cross-talk between two distinct growth factor receptors. FASEB J. 2003;17(12):1640\u20131647.","journal-title":"FASEB J"},{"issue":"3","key":"4349_CR192","doi-asserted-by":"publisher","first-page":"171","DOI":"10.4143\/crt.2005.37.3.171","volume":"37","author":"WS Moon","year":"2005","unstructured":"Moon WS, et al. Co-expression of cox-2, c-MET and beta-catenin in cells forming invasive front of gallbladder cancer. Cancer Res Treat. 2005;37(3):171\u2013176.","journal-title":"Cancer Res Treat"},{"issue":"15","key":"4349_CR193","doi-asserted-by":"publisher","first-page":"2186","DOI":"10.1096\/fasebj.13.15.2186","volume":"13","author":"MK Jones","year":"1999","unstructured":"Jones MK, et al. HGF triggers activation of the COX-2 gene in rat gastric epithelial cells: action mediated through the ERK2 signaling pathway. FASEB J. 1999;13(15):2186\u20132194.","journal-title":"FASEB J"},{"key":"4349_CR194","doi-asserted-by":"publisher","DOI":"10.1016\/j.tiv.2020.104912","volume":"67","author":"P. Sharma","year":"2020","unstructured":"Sharma P, Cadwell TS, Rivera MN, Gullapalli RR.Cadmium exposure activates Akt\/ERK Signaling and pro-inflammatory COX-2 expression in human gallbladder epithelial cells via a ROS dependent mechanism. Toxicol In Vitro. 2020;67:104912.","journal-title":"Toxicol In Vitro"},{"issue":"7","key":"4349_CR195","doi-asserted-by":"publisher","first-page":"964","DOI":"10.7150\/ijbs.4564","volume":"8","author":"EC Connolly","year":"2012","unstructured":"Connolly EC, Freimuth J, Akhurst RJ. Complexities of TGF-\u03b2 targeted cancer therapy. Int J Biol Sci. 2012;8(7):964\u2013978.","journal-title":"Int J Biol Sci"},{"issue":"10","key":"4349_CR196","doi-asserted-by":"publisher","first-page":"616","DOI":"10.1038\/nrm3434","volume":"13","author":"J Massagu\u00e9","year":"2012","unstructured":"Massagu\u00e9 J. TGF\u03b2 signalling in context. Nat Rev Mol Cell Biol. 2012;13(10):616\u2013630.","journal-title":"Nat Rev Mol Cell Biol"},{"key":"4349_CR197","doi-asserted-by":"publisher","first-page":"685","DOI":"10.1016\/S0092-8674(03)00432-X","volume":"113","author":"Y Shi","year":"2003","unstructured":"Shi Y, Massagu\u00e9 J. Mechanisms of TGF-beta signaling from cell membrane to the nucleus. Cell. 2003;113:685\u2013700.","journal-title":"Cell"},{"issue":"1","key":"4349_CR198","doi-asserted-by":"publisher","first-page":"128","DOI":"10.1038\/cr.2008.328","volume":"19","author":"YE Zhang","year":"2009","unstructured":"Zhang YE. Non-Smad pathways in TGF-beta signaling. Cell Res. 2009;19(1):128\u2013139.","journal-title":"Cell Res"},{"key":"4349_CR199","doi-asserted-by":"publisher","first-page":"zcaa024","DOI":"10.1093\/narcan\/zcaa024","volume":"2","author":"MK Grundy","year":"2020","unstructured":"Grundy MK, Buckanovich RJ, Bernstein KA. Regulation and pharmacological targeting of RAD51 in cancer. NAR Cancer. 2020;2:zcaa024.","journal-title":"NAR Cancer"},{"issue":"2","key":"4349_CR200","doi-asserted-by":"publisher","first-page":"111","DOI":"10.7150\/ijbs.23230","volume":"14","author":"M Zhao","year":"2018","unstructured":"Zhao M, Mishra L, Deng CX. The role of TGF-\u03b2\/SMAD4 signaling in cancer. Int J Biol Sci. 2018;14(2):111\u2013123.","journal-title":"Int J Biol Sci"},{"key":"4349_CR201","doi-asserted-by":"publisher","first-page":"935593","DOI":"10.3389\/fonc.2022.935593","volume":"12","author":"Z Wang","year":"2022","unstructured":"Wang Z, Jia R, Wang L, Yang Q, Hu X, Fu Q, Zhang X, Li W, Ren Y. The Emerging Roles of Rad51 in Cancer and Its Potential as a Therapeutic Target. Front Oncol. 2022;12:935593.","journal-title":"Front Oncol"},{"key":"4349_CR202","doi-asserted-by":"crossref","unstructured":"McKenzie K, Grundy RJ, Buckanovich, Kara A, Bernstein. Regulation and pharmacological targeting of RAD51 in cancer. NAR Cancer. September 2020,2(3):zcaa024.","DOI":"10.1093\/narcan\/zcaa024"},{"issue":"12","key":"4349_CR203","doi-asserted-by":"publisher","first-page":"2930","DOI":"10.3390\/cancers13122930","volume":"13","author":"E Orhan","year":"2021","unstructured":"Orhan E, Velazquez C, Tabet I, Sardet C, Theillet C. Regulation of RAD51 at the Transcriptional and Functional Levels: What Prospects for Cancer Therapy? Cancers. 2021;13(12):2930.","journal-title":"Cancers"},{"key":"4349_CR204","doi-asserted-by":"publisher","first-page":"858756","DOI":"10.3389\/fonc.2022.858756","volume":"12","author":"H Liu","year":"2022","unstructured":"Liu H, Weng J. A Pan-Cancer Bioinformatic Analysis of RAD51 Regarding the Values for Diagnosis, Prognosis, and Therapeutic Prediction. Front Oncol. 2022;12:858756.","journal-title":"Front Oncol"},{"key":"4349_CR205","doi-asserted-by":"crossref","unstructured":"Lin J et al. Precision oncology for gallbladder cancer: insights from genetic alterations and clinical practice. Ann Transl Med. 20197(18) :467.","DOI":"10.21037\/atm.2019.08.67"},{"key":"4349_CR206","doi-asserted-by":"publisher","first-page":"7905","DOI":"10.3390\/ijms24097905","volume":"24","author":"M Pan","year":"2023","unstructured":"Pan M, et al. RAD51 Inhibition Shows Antitumor Activity in Hepatocellular Carcinoma. Int J Mol Sci. 2023;24:7905.","journal-title":"Int J Mol Sci"},{"key":"4349_CR207","doi-asserted-by":"crossref","unstructured":"Gao Z et al. KRAS acting through ERK signaling stabilizes PD-L1 via inhibiting autophagy pathway in intrahepatic cholangiocarcinoma. Cancer Cell. 2022 ,22:128.","DOI":"10.1186\/s12935-022-02550-w"},{"issue":"24","key":"4349_CR208","doi-asserted-by":"publisher","first-page":"3719","DOI":"10.3748\/wjg.v11.i24.3719","volume":"11","author":"LN Xu","year":"2005","unstructured":"Xu LN, Zou SQ, Wang JM. Action and mechanism of Fas and Fas ligand in immune escape of gallbladder carcinoma. World J Gastroenterol. 2005;11(24):3719\u20133723.","journal-title":"World J Gastroenterol"},{"key":"4349_CR209","doi-asserted-by":"publisher","first-page":"2406633","DOI":"10.1002\/advs.202406633","volume":"11","author":"C Zhao","year":"2024","unstructured":"Zhao C, Zhao J, Zhang Y, Zhu Y, Yang Z, Liu S, Tang Q, Yang Y, Wang H, Shu Y, Dong P, Wu X, Gong W. PTBP3 Mediates IL-18 Exon Skipping to Promote Immune Escape in Gallbladder Cancer. Adv Sci. 2024;11:2406633.","journal-title":"Adv Sci"},{"key":"4349_CR210","doi-asserted-by":"publisher","first-page":"636568","DOI":"10.3389\/fimmu.2021.636568","volume":"12","author":"K Dhatchinamoorthy","year":"2021","unstructured":"Dhatchinamoorthy K, Colbert JD, Rock KL. Cancer Immune Evasion Through Loss of MHC Class I Antigen Presentation. Front Immunol. 2021;12:636568.","journal-title":"Front Immunol"},{"key":"4349_CR211","doi-asserted-by":"crossref","unstructured":"Chen Y, Zhang J, Ding Y, Zhu F, Chen Y. Colorectal cancer pathogenesis, oncogenic signaling networks and targeted therapeutic advances. Mol Biomed.2026, 7:32 .","DOI":"10.1186\/s43556-026-00433-4"},{"key":"4349_CR212","doi-asserted-by":"crossref","unstructured":"Jaiswar D, et al. Integrative Molecular Insights Into Epidemiological, Genetic, and Metabolic Risk Factors of Gallbladder Cancer: Implications for Biomarkers, Therapeutic Targeting, and Future Perspectives. Cancer Control. Feb. 2026;33:10732748261433619.","DOI":"10.1177\/10732748261433619"},{"key":"4349_CR213","first-page":"151","volume":"8","author":"K Sahu","year":"2025","unstructured":"Sahu K, Satapathy T, Sahu P, Chandrakar O. Molecular Biomarkers and Nano-Immunopharmacology in Inflammatory Carcinoma: Bridging Mechanisms and Therapeutic Translation. Adv Biomark Sci Technol. 2025;8:151-171.","journal-title":"Adv Biomark Sci Technol"},{"key":"4349_CR214","doi-asserted-by":"publisher","first-page":"243","DOI":"10.1186\/s12885-018-4147-6","volume":"18","author":"P Flux\u00e1","year":"2018","unstructured":"Flux\u00e1 P, et al. High CD8\u2009+\u2009and absence of Foxp3\u2009+\u2009T lymphocytes infiltration in gallbladder tumors correlate with prolonged patients survival. BMC Cancer. 2018;18:243.","journal-title":"BMC Cancer"},{"key":"4349_CR215","doi-asserted-by":"publisher","first-page":"766","DOI":"10.1186\/s12885-018-4651-8","volume":"18","author":"J Lin","year":"2018","unstructured":"Lin J, Long J, Wan X, et al. Classification of gallbladder cancer by assessment of CD8\u2009+\u2009TIL and PD-L1 expression. BMC Cancer. 2018;18:766.","journal-title":"BMC Cancer"},{"key":"4349_CR216","doi-asserted-by":"crossref","unstructured":"Zhang Y, Zuo C, Li Y, Liu L, Yang B, Xia J, Cui J, Xu K, Wu X. Wei Gong, Yingbin Liu.Single-cell characterization of infiltrating T cells identifies novel targets for gallbladder. cancer immunotherapy Cancer Lett.2024; 586:216675 .","DOI":"10.1016\/j.canlet.2024.216675"},{"issue":"9","key":"4349_CR217","doi-asserted-by":"publisher","first-page":"1736","DOI":"10.1038\/sj.bjc.6601331","volume":"89","author":"Y Nakakubo","year":"2003","unstructured":"Nakakubo Y, Miyamoto M, Cho Y, et al. Clinical significance of immune cell infiltration within gallbladder cancer. Br J Cancer. 2003;89(9):1736\u20131742.","journal-title":"Br J Cancer"},{"key":"4349_CR218","doi-asserted-by":"publisher","first-page":"1850","DOI":"10.3390\/vaccines10111850","volume":"10","author":"MA Dar","year":"2022","unstructured":"Dar MA, et al. Designing of Peptide Based Multi-Epitope Vaccine Construct against Gallbladder Cancer Using Immunoinformatics and Computational Approaches. Vaccines (Basel). 2022;10:1850.","journal-title":"Vaccines (Basel)"},{"key":"4349_CR219","doi-asserted-by":"publisher","first-page":"3404","DOI":"10.3390\/cancers12113404","volume":"12","author":"S Han","year":"2020","unstructured":"Han S, et al. A Perspective on Cell Therapy and Cancer Vaccine in Biliary Tract Cancers (BTCs). Cancers (Basel). 2020;12:3404.","journal-title":"Cancers (Basel)"},{"key":"4349_CR220","doi-asserted-by":"publisher","first-page":"1025608","DOI":"10.3389\/fimmu.2022.1025608","volume":"13","author":"Q Feng","year":"2022","unstructured":"Feng Q, et al. Advances in CAR T-cell therapy in bile duct, pancreatic, and gastric cancers. Front Immunol. 2022;13:1025608.","journal-title":"Front Immunol"},{"key":"4349_CR221","doi-asserted-by":"crossref","unstructured":"Lopez E et al. Preclinical evaluation of chimeric antigen receptor T cells targeting the carcinoembryonic antigen as a potential immunotherapy for gallbladder cancer. OncoImmunology. 2023;12(1):2225291. .","DOI":"10.1080\/2162402X.2023.2225291"},{"key":"4349_CR222","doi-asserted-by":"publisher","first-page":"1183619","DOI":"10.3389\/fphar.2023.1183619","volume":"14","author":"Y Zhou","year":"2023","unstructured":"Zhou Y, Yuan K, Yang Y, Ji Z, Zhou D, Ouyang J, Wang Z, Wang F, Liu C, Li Q, Zhang Q, Li Q. Shan X and Zhou J.Gallbladder cancer: current and future treatment options. Front Pharmacol. 2023;14:1183619.","journal-title":"Front Pharmacol"},{"issue":"2","key":"4349_CR223","doi-asserted-by":"publisher","first-page":"229","DOI":"10.1016\/j.suc.2015.12.007","volume":"96","author":"M Qadan","year":"2016","unstructured":"Qadan M, Kingham TP. Technical Aspects of Gallbladder Cancer Surgery. Surg Clin North Am. 2016;96(2):229\u2013245.","journal-title":"Surg Clin North Am"},{"key":"4349_CR224","doi-asserted-by":"publisher","first-page":"230","DOI":"10.1038\/s41392-020-00324-2","volume":"5","author":"X Song","year":"2020","unstructured":"Song X, et al. Overview of current targeted therapy in gallbladder cancer. Signal Transduct Target Ther. 2020;5:230.","journal-title":"Signal Transduct Target Ther"},{"key":"4349_CR225","doi-asserted-by":"publisher","first-page":"113564","DOI":"10.1016\/j.ejca.2024.113564","volume":"199","author":"BHEA Ten Haaft","year":"2024","unstructured":"Ten Haaft BHEA, et al. Revolutionizing anti-HER2 therapies for extrahepatic cholangiocarcinoma and gallbladder cancer: Current advancements and future perspectives. Eur J Cancer. 2024;199:113564.","journal-title":"Eur J Cancer"}],"container-title":["Cancer Cell International"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12935-026-04349-5","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12935-026-04349-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12935-026-04349-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,24]],"date-time":"2026-07-24T04:12:40Z","timestamp":1784866360000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s12935-026-04349-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,27]]},"references-count":225,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["4349"],"URL":"https:\/\/doi.org\/10.1186\/s12935-026-04349-5","relation":{},"ISSN":["1475-2867"],"issn-type":[{"value":"1475-2867","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5,27]]},"assertion":[{"value":"16 October 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 May 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 May 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Disclosures"}}],"article-number":"271"}}